Journal ArticleDOI
Management of gastric cancer in Asia: resource-stratified guidelines
Lin Shen,Yan Shen Shan,Huang Ming Hu,Timothy J. Price,Bhawna Sirohi,Kun-Huei Yeh,Yi-Hsin Yang,Takeshi Sano,Han-Kwang Yang,Xiaotian Zhang,Sook Ryun Park,Masashi Fujii,Yoon-Koo Kang,Li-Tzong Chen,Li-Tzong Chen +14 more
TLDR
This work aims to provide a stepwise strategy for management of gastric cancer applicable to different levels of health-care resources in Asian countries, using the categories of basic, limited, enhanced, and maximum level.Abstract:
Summary Gastric cancer is the fourth most common cancer globally, and is the second most common cause of death from cancer worldwide. About three-quarters of newly diagnosed cases in 2008 were from Asian countries. With a high mortality-to-incidence ratio, management of gastric cancer is challenging. We discuss evidence for optimum management of gastric cancer in aspects of screening and early detection, diagnosis, and staging; endoscopic and surgical intervention; and the concepts of perioperative, postoperative, and palliative chemotherapy and use of molecularly targeted therapy. Recommendations are formulated on the basis of the framework provided by the Breast Health Global Initiative, using the categories of basic, limited, enhanced, and maximum level. We aim to provide a stepwise strategy for management of gastric cancer applicable to different levels of health-care resources in Asian countries.read more
Citations
More filters
Journal ArticleDOI
Risk factors for lymph node metastasis of early gastric cancers in patients younger than 40
TL;DR: Given the high risk of lymph node involvement in young patients with early gastric cancer, both endoscopic and surgical resection procedures should be performed with caution, and active postoperative surveillance is warranted.
Journal ArticleDOI
Impact of delayed care on surgical management of patients with gastric cancer in a low-resource setting.
Allison N. Martin,Allison Silverstein,Allison Silverstein,Allison Silverstein,Robinson Ssebuufu,Joseph Lule,Pacifique Mugenzi,Alexandra E. Fehr,Tharcisse Mpunga,Lawrence N. Shulman,Lawrence N. Shulman,Paul H. Park,Paul H. Park,Paul H. Park,Ainhoa Costas-Chavarri,Ainhoa Costas-Chavarri +15 more
TL;DR: Perioperative management of gastric cancer in Rwanda is described, which shows promising results in terms of survival and morbidity and the need to select patients suitable for surgery based on prior history.
Journal ArticleDOI
A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
Cheng Xiao,Jiong Qian,Yulong Zheng,Fang Song,Qiangfeng Wang,Haiping Jiang,Chenyu Mao,Nong Xu +7 more
TL;DR: The biweekly SOX regimen as first-line treatment was active and well tolerated in Chinese patients with metastatic or advanced gastric cancer.
Journal ArticleDOI
Peperomin E Induces Promoter Hypomethylation of Metastatic-Suppressor Genes and Attenuates Metastasis in Poorly Differentiated Gastric Cancer.
TL;DR: PepE can dose-dependently suppress invasion and migration of poorly-differentiated gastric cancer cells in vitro and in vivo with low toxicity against normal cells and may also exhibit potential as a DNA methylation inhibitor for use in epigenetic cancer therapy.
Journal ArticleDOI
Heat shock-induced HIKESHI protects cell viability via nuclear translocation of heat shock protein 70
Toru Yanoma,Kyoichi Ogata,Takehiko Yokobori,Munenori Ide,Erito Mochiki,Yoshitaka Toyomasu,Mitsuhiro Yanai,Norimichi Kogure,Akiharu Kimura,Masaki Suzuki,Nobuhiro Nakazawa,Tuya Bai,Tetsunari Oyama,Takayuki Asao,Ken Shirabe,Hiroyuki Kuwano +15 more
TL;DR: The results suggest that HIKESHI is a marker of cancer progression and that the combination of HIKesHI inhibition and hyperthermia is a therapeutic tool for refractory GC.
References
More filters
Journal ArticleDOI
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
TL;DR: The results for 20 world regions are presented, summarizing the global patterns for the eight most common cancers, and striking differences in the patterns of cancer from region to region are observed.
Journal ArticleDOI
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang,Eric Van Cutsem,A. Feyereislova,Hyun Cheol Chung,Lin Shen,Akira Sawaki,Florian Lordick,Atsushi Ohtsu,Yasushi Omuro,Taroh Satoh,G. Aprile,Evgeny Kulikov,Julie Hill,Michaela Lehle,Josef Rüschoff,Yoon-Koo Kang +15 more
TL;DR: Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer.
Journal ArticleDOI
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
David Cunningham,William H. Allum,Sally P. Stenning,Jeremy Thompson,Marianne Nicolson,J. Howard Scarffe,F. Lofts,Stephen Falk,Timothy Iveson,David Smith,Ruth E Langley,Monica Verma,Simon Weeden,Yu Jo Chua +13 more
TL;DR: In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival.
Journal ArticleDOI
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
Peter Malfertheiner,Francis Mégraud,John Atherton,Anthony T. R. Axon,Franco Bazzoli,Gian Franco Gensini,Javier P. Gisbert,David Y. Graham,Ernst J. Kuipers +8 more
TL;DR: In this 4th edition of the Maastricht consensus report aspects related to the clinical role of H pylori were looked at again in 2010, with recommendations to guide doctors involved in the management of this infection associated with various clinical conditions.
Journal ArticleDOI
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
TL;DR: Capecitabine and oxaliplatin are as effective as fluorouracil and cisplatin, respectively, in patients with previously untreated esophagogastric cancer, in a two-by-two design.